Sun Pharma Advanced Research Company’s (SPARC) Combitide Starhaler for asthma and COPD is shortlisted as a finalist at the 2012 Medical Design Excellence Awards (MDEA) to be held in Philadelphia this May. Combitide Starhaler has been introduced in the Indian market last year by Sun Pharmaceutical Industries.
Combitide Starhaler is a novel, high performance multi dose dry powder inhaler. This next generation DPI improves on current marketed devices. The inhaler has a uniform delivery profile that ensures that the full intended metered dose of the drug is administered to the deep lung, regardless of the strength of the patient’s intake of breath. This step change in inhaler technology offers a reliable and easy to use device, particularly for patients with impaired lung function.
MDEA is the premier awards program for the medical technology community, and the only awards program that exclusively recognizes contributions and advances in the design of medical products.
| Company Name | CMP |
|---|---|
| Syngene Internation. | 435.70 |
| Indegene | 486.80 |
| CMS Info Systems | 318.00 |
| JITF Infralogistics | 338.00 |
| Sagility | 42.95 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: